Triphenylmethanol

Triphenylmethanol

SCHEMBL16601082

OC(c1ccccc1)(c1ccccc1)c1ccccc1.OC(c1ccccc1)c1ccccc1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.44
TSHR P16473 2/20 0.40
CYP19A1 P11511 2/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
LMNA P02545 3/20 0.39
MAPK1 P28482 1/20 0.39
CRHBP P24387 1/20 0.39
CRHR2 Q13324 1/20 0.39
KCNA5 P22460 2/20 0.38
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triphenylmethanol SCHEMBL700 0.82 CYP19A1 (0.50) TSHRCYP19A1CRHBPCRHR2CYP2C9
Diphenylmethanol SCHEMBL41571 0.82 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1TSHRCA12CA1
Diphenylmethanol SCHEMBL11564700 0.82 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1TSHRCA12CA1
Triphenylmethanol SCHEMBL1332873 0.82 CYP19A1 (0.50) TSHRCYP19A1CRHBPCRHR2CYP2C9
Diphenylmethanol SCHEMBL6434457 0.82 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1TSHRCA12CA1
Triphenylmethanol SCHEMBL456603 0.82 CYP19A1 (0.50) TSHRCYP19A1CRHBPCRHR2CYP2C9
Diphenylmethanol SCHEMBL10868602 0.82 SMN1; SMN2 (0.61) SMN1; SMN2L3MBTL1TSHRCA12CA1
Diphenylmethanol SCHEMBL15641329 0.79 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1TSHRCA12CA1
Triphenylmethanol SCHEMBL1565321 0.79 CYP19A1 (0.48) TSHRCYP19A1CRHBPCRHR2CYP2C9
Diphenylmethanol SCHEMBL8164003 0.79 SMN1; SMN2 (0.58) SMN1; SMN2L3MBTL1TSHRCA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10350196-B2 Long-acting spiro-isoxazoline formulations ZOETIS SERVICES LLC (US) 2019-07-16 US disclosed
US-20160235720-A1 Long-Acting Spiro-Isoxazoline Formulations ZOETIS SERVICES LLC 2016-08-18 US disclosed
EP-3052080-A1 LONG-ACTING SPIRO-ISOXAZOLINE FORMULATIONS Zoetis Services LLC (US) 2016-08-10 EP disclosed
WO-2015048371-A1 LONG-ACTING SPIRO-ISOXAZOLINE FORMULATIONS ZOETIS LLC (US) 2015-04-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235720-A1 Long-Acting Spiro-Isoxazoline Formulations CYP2A7, CYP3A7, AVPR2 SMN1; SMN2 1839/4885L3MBTL1 4773/4885TSHR 2598/4885
US-10350196-B2 Long-acting spiro-isoxazoline formulations CYP2A7, CYP3A7, AVPR2 SMN1; SMN2 1839/4885L3MBTL1 4773/4885TSHR 2598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.